Valproic acid is a selective antiproliferative agent in estrogen-sensitive breast cancer cells

被引：53

作者：

Fortunati, Nicoletta ^{[1
]}

Bertino, Silvia ^{[1
]}

Costantino, Lucia ^{[2
]}

Bosco, Ornella ^{[2
]}

Vercellinatto, Ilenia ^{[3
]}

Catalano, Maria Graziella ^{[2
]}

Boccuzzi, Giuseppe ^{[1
,2
]}

机构：

[1] ASO Giovanni Battista, I-10126 Turin, Italy

[2] Univ Turin, Dept Clin Pathol, I-10126 Turin, Italy

[3] Univ Turin, Dept Expt Med & Oncol, I-10126 Turin, Italy

来源：

CANCER LETTERS | 2008年 / 259卷 / 02期

关键词：

apoptosis; breast cancer; cell cycle; valproic acid;

D O I：

10.1016/j.canlet.2007.10.006

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Treatment efficacy of breast cancer can be impaired by cell resistance. The aim of the study was to investigate the anti-tumour effects of valproic acid (VPA), the only clinically available historic deacetylase inhibitor, on both estrogen-sensitive and -insensitive breast cancer cells. VPA, at a concentration lacking severe adverse effects in human, reduces cell viability in estrogen-sensitive cell lines, inducing p21 expression and impairing cell cycle. In ZR-75-1, cell cycle is selectively arrested in G1, whereas MCF-7 cells massively accumulated in sub-G1. Actually, in MCF-7 cells, VPA induces apoptosis, down-regulates Bcl-2 and up-regulates Bak expression. In conclusion, VPA is a powerful antiproliferative agent in estrogen-sensitive breast cancer cells, making this drug of clinical interest as a new approach to treat breast cancer. (C) 2007 Elsevier Ireland Ltd. All rights reserved.

引用

页码：156 / 164

页数：9

共 35 条

[1] Valproic acid induces apoptosis and cell cycle arrest in poorly differentiated thyroid cancer cells [J].